Andrea Tan
Stock Analyst at Goldman Sachs
(1.52)
# 3,569
Out of 5,241 analysts
47
Total ratings
40%
Success rate
-7.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $306.29 | +6.76% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $76.67 | +10.86% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $109.14 | +106.16% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $3.45 | +131.88% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $62.48 | -18.37% | 4 | May 5, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $6.90 | -13.04% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $6.90 | -71.01% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $37.02 | -94.60% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $4.09 | +486.80% | 2 | Aug 4, 2023 | |
| FATE Fate Therapeutics | Maintains: Sell | $10 → $4 | $1.76 | +127.92% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $523.69 | -28.39% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $14.63 | +446.82% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $306.29
Upside: +6.76%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $76.67
Upside: +10.86%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $109.14
Upside: +106.16%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $3.45
Upside: +131.88%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $62.48
Upside: -18.37%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $6.90
Upside: -13.04%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $6.90
Upside: -71.01%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $37.02
Upside: -94.60%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $4.09
Upside: +486.80%
Fate Therapeutics
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.76
Upside: +127.92%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $523.69
Upside: -28.39%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $14.63
Upside: +446.82%